Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine

详细信息    查看全文

• 作者：M. Elizabeth Fini^a ; ² ; ^{efini@med.usc.edu} ; Stephen G. Schwartz^b ; ² ; ^{sschwartz2@med.miami.edu} ; Xiaoyi Gao^c ; ² ; ^rgao@uic.edu ; Shinwu Jeong^d ; ² ; ^{shinwuje@med.usc.edu} ; Nitin Patel^e ; ¹ ; ² ; ^{nitinusc@gmail.com} ; Tatsuo Itakura^e ; ² ; ^{itakura@med.usc.edu} ; Marianne O. Price^f ; ² ; ^{marianneprice@cornea.org} ; Francis W. Price Jr.^g ; ² ; ^{francisprice@pricevisiongroup.net} ; Rohit Varma^h ; ² ; ^{Rohit.Varma@med.usc.edu} ; W. Daniel Stamerⁱ ; ² ; ^{dan.stamer@duke.edu}
• 关键词：Ocular hypertension ; Glaucoma ; Glucocorticoid ; Pharmacogenomics ; Precision medicine ; Ophthalmology
• 刊名：Progress in Retinal and Eye Research
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：56
• 期：Complete
• 页码：58-83
• 全文大小：2254 K
• 卷排序：56

文摘

Glucocorticoids cause ocular hypertension/glaucoma, but only in a subset of patients. Glucocorticoids affect expression of many genes, variants in which could alter response. Pharmacogenomics can identify genetic variants affecting glucocorticoid sensitivity. The location of variants can pinpoint new causative genes and clinically relevant pathways. Testing for identified variants can be used to predict glucocorticoid sensitivity in patients.